THE ARISING · Markets & Strategy
Rubedo's Topical Drug Cut Skin Epigenetic Age by 2.1 Years, Company Says
Rubedo Life Sciences says a topical drug lowered the epigenetic age of treated patients' skin by 2.1 years on average by one measure after just four weeks, according to Longevity.Technology. The report is a company presentation of a small early trial, and we could not read the original page.
The company presented Phase 1b results at the ARDD conference. Patients with atopic dermatitis used the topical drug, RLS-1496, for four weeks. Across 11 paired samples, average skin epigenetic age fell by 2.1 years, according to the MitraBio aging clock, run by an independent lab. The best responder measured 11.7 years younger at Day 63, about a month after the last application.
Rubedo also reported fewer senescence markers and more collagen in biopsies, including a 10% rise in type III collagen fibers. Senescent cells are aged cells that stop dividing. RLS-1496 targets a protein called GPX4 and pushes vulnerable senescent cells toward ferroptosis, a form of cell death. Rubedo calls this approach "SenoAdaptive."
One finding stands out, and it comes with a caveat. Among about 10,800 blood proteins screened, the inflammatory marker CCL22 fell 17% in treated patients and rose 19% in the vehicle group. This happened even though most patients had no detectable drug in their blood. But the vehicle group had only four patients, so the comparison is thin.
For competitive positioning, the data show Rubedo reporting results beyond atopic dermatitis. The company also reported a 49% mean lesion reduction in 22 patients in its actinic keratosis program. A Phase 2a trial in androgenetic alopecia is slated to begin in October. The report does not say whether those programs use RLS-1496 or the same mechanism, how the results compare with rivals, or what regulators will accept as an endpoint.
That last point matters for the market. An epigenetic clock reading is not an established regulatory endpoint, and the report does not address it. The results come from a small trial in atopic dermatitis patients, and the report does not say whether the age change translates into clinical benefit. This is the weakest part of the story: a drop in a clock reading is not the same as healthier or better-looking skin.
RLS-1496 is an investigational drug.
What to watch next
The start of the alopecia Phase 2a trial, and whether Rubedo reports larger, controlled data showing the aging-clock change tracks real clinical outcomes.
Rubedo's Topical Drug Cut Skin Epigenetic Age by 2.1 Years, Company Says Social Security Sets 3.6% Benefit Increase for 2027, Largest Since 2023 Unemployed Workers 55 to 64 Average Over Eight Months Without a Job Alector Prices $75 Million Stock Offering to Fund Neurodegeneration Work CMS Proposes Medicare Advantage Directory and Part D PBM Rules